Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
13-Aug-2025 | 5,240 | 5,400 | 5,240 | 5,388.5 | 97,221 | 4,80,47,27,346 | 3,57,537 |
14-Aug-2025 | 5,355 | 5,423.5 | 5,315 | 5,347.5 | 25,606 | 1,49,15,40,687.5 | 1,43,165 |
18-Aug-2025 | 5,347.5 | 5,395.5 | 5,328.5 | 5,346 | 18,945 | 46,89,25,753 | 51,598 |
19-Aug-2025 | 5,353 | 5,420 | 5,297.5 | 5,392 | 29,948 | 1,19,93,16,316.5 | 1,38,628 |
20-Aug-2025 | 5,400 | 5,425 | 5,369.5 | 5,393 | 20,937 | 75,56,16,695 | 81,146 |
21-Aug-2025 | 5,393 | 5,474 | 5,362.5 | 5,422 | 28,009 | 74,66,19,743.5 | 73,527 |
22-Aug-2025 | 5,470 | 5,479 | 5,420 | 5,426 | 17,128 | 54,22,69,678.5 | 45,985 |
25-Aug-2025 | 5,430 | 5,474 | 5,397.5 | 5,415.5 | 17,057 | 77,44,01,916 | 96,070 |
26-Aug-2025 | 5,415.5 | 5,438 | 5,373.5 | 5,422 | 30,732 | 1,02,24,37,228 | 1,37,946 |
28-Aug-2025 | 5,420 | 5,434 | 5,359.5 | 5,376 | 23,552 | 61,82,60,796 | 78,906 |
29-Aug-2025 | 5,376 | 5,388 | 5,291 | 5,303.5 | 16,789 | 61,63,15,503.5 | 73,589 |
01-Sep-2025 | 5,310 | 5,348.5 | 5,273 | 5,300.5 | 10,418 | 29,91,45,966 | 38,846 |
02-Sep-2025 | 5,321.5 | 5,340 | 5,204.5 | 5,246.5 | 19,009 | 60,66,00,410 | 69,767 |
03-Sep-2025 | 5,252 | 5,317 | 5,252 | 5,292 | 10,642 | 38,49,17,564.5 | 45,385 |
04-Sep-2025 | 5,380 | 5,380 | 5,289.5 | 5,301.5 | 20,626 | 70,07,29,780.5 | 88,584 |
05-Sep-2025 | 5,323.5 | 5,369 | 5,277 | 5,333.5 | 26,451 | 1,26,61,36,372.5 | 1,85,706 |
08-Sep-2025 | 5,340 | 5,382.5 | 5,300.5 | 5,333 | 10,277 | 21,23,74,723 | 21,404 |
09-Sep-2025 | 5,321 | 5,370 | 5,321 | 5,336 | 20,893 | 49,16,37,580.5 | 65,729 |
10-Sep-2025 | 5,359.5 | 5,400 | 5,298 | 5,320.5 | 18,313 | 1,01,71,83,257 | 1,38,816 |
11-Sep-2025 | 5,361.5 | 5,429 | 5,326.5 | 5,393.5 | 15,709 | 1,90,43,48,444 | 2,99,879 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
